Stock Events

Stock Events

Delcath Systems 

€9.09
0
+€0.22+2.44% Monday 06:03

Statistics

Day High
9.09
Day Low
9.09
52W High
15.9
52W Low
7.4
Volume
-
Avg. Volume
-
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

7MayExpected
Q4 2025
Next
-0.08
-0.07
-0.06
-0.04
Expected EPS
-0.08290086477
Actual EPS
N/A

People Also Follow

This list is based on the watchlists of people on Stock Events who follow DV3R.MU. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
BlackRock Technology and Private Equity Term Trust
BTX
Mkt Cap939.52M
BioTime, Inc. focuses on developing and commercializing products in the field of regenerative medicine and blood filtration, directly competing with Delcath's cancer treatment technologies.
Johnson & Johnson
JNJ
Mkt Cap546.9B
Johnson & Johnson, through its subsidiary Janssen Pharmaceuticals, develops treatments for various cancers, competing with Delcath's hepatic delivery systems.
Bristol-Myers Squibb
BMY
Mkt Cap118.87B
Bristol-Myers Squibb Company offers a range of cancer treatments, including therapies that could be seen as alternatives to Delcath's percutaneous hepatic perfusion.
Merck
MRK
Mkt Cap277.02B
Merck & Co., Inc. has a strong portfolio in oncology, including therapies that could compete with Delcath's methods for treating liver cancers.
Pfizer
PFE
Mkt Cap149.77B
Pfizer Inc. develops and markets drugs for various cancer types, potentially competing with Delcath's targeted liver cancer treatments.
Novartis
NVS
Mkt Cap279.67B
Novartis AG has a broad oncology segment that includes treatments for liver cancer, posing competition to Delcath's specialized procedures.
Abbvie
ABBV
Mkt Cap365.43B
AbbVie Inc. engages in the discovery and marketing of a range of oncology treatments, which could serve as alternatives to Delcath's technology.
Gilead Sciences
GILD
Mkt Cap163.4B
Gilead Sciences, Inc. offers therapies for liver diseases, including cancer, which could compete with Delcath's liver-directed therapies.
AMGEN
AMGN
Mkt Cap178B
Amgen Inc. has a diverse oncology portfolio, including treatments that could compete with Delcath's approach to cancer treatment.

About

Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. Its clinical development program for HEPZATO is the FOCUS clinical trial for patients with metastatic hepatic dominant Uveal Melanoma to investigate objective response rate in metastatic uveal melanoma. It also provides HEPZATO as a stand-alone medical device under the CHEMOSAT Hepatic Delivery System trade name for Melphalan or CHEMOSAT for medical centers to treat a range of liver cancers in Europe. Delcath Systems, Inc. was incorporated in 1988 and is headquartered in New York, New York.
Show more...
CEO
Mr. Gerard J. Michel MBA, MS
Employees
96
Country
United States
ISIN
US24661P8077

Listings

MU
DE
DV3R.MU
STU
DE
DV3R.STU
F
DE
DV3R.F
XNAS
US
DCTH

0 Comments

Share your thoughts

FAQ

What is Delcath Systems stock price today?▼
The current price of DV3R.MU is €9.09 EUR — it has increased by +2.44% in the past 24 hours. Watch Delcath Systems stock price performance more closely on the chart.
What is Delcath Systems stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Delcath Systems stocks are traded under the ticker DV3R.MU.
Is Delcath Systems stock price growing?▼
DV3R.MU stock has fallen by -2.03% compared to the previous week, the month change is a +11.48% rise, over the last year Delcath Systems has showed a -15.08% decrease.
When is the next Delcath Systems earnings date?▼
Delcath Systems is going to release the next earnings report on May 07, 2026.
What were Delcath Systems earnings last quarter?▼
DV3R.MU earnings for the last quarter are -0.04 EUR per share, whereas the estimation was -0.05 EUR resulting in a +20.62% surprise. The estimated earnings for the next quarter are N/A EUR per share.
How many employees does Delcath Systems have?▼
As of May 06, 2026, the company has 96 employees.
In which sector is Delcath Systems located?▼
Delcath Systems operates in the Health & Wellness sector.
When did Delcath Systems complete a stock split?▼
Delcath Systems has not had any recent stock splits.
Where is Delcath Systems headquartered?▼
Delcath Systems is headquartered in Queensbury, United States.